Sawada M, Yamasaki M, Urabe T, Ozaki M, Yanagita T, Takayama K, Taki I
Department of Obstetrics and Gynecology, Kure National Hospital, Japan.
Asia Oceania J Obstet Gynaecol. 1990 Dec;16(4):315-21. doi: 10.1111/j.1447-0756.1990.tb00355.x.
CAP, a multiple-drug combination therapy using cyclophosphamide (750 mg/m2), adriamycin (20-30 mg/m2) and cisplatin (50-75 mg/m2), was applied to 69 cases of epithelial ovarian cancer. The results of this therapy were compared with those of FAM (involving 5-fluorouracil, cyclophosphamide and mitomycin C) in 47 cases of the same cancer, retrospectively. The 5-year survival rate was 61.6% for cases treated with CAP and 56.3% for cases treated with FAM. All 9 patients at stage Ia treated with CAP are free of disease, however, 3 patients out of 13 at stage Ia treated with FAM experienced a recurrence of the disease and died. In stage III and IV cases with detectable lesions, a response was observed in 61.3% (19/31) treated with CAP and in 10.5% (2/19) treated with FAM.
环磷酰胺（750毫克/平方米）、阿霉素（20 - 30毫克/平方米）和顺铂（50 - 75毫克/平方米）的联合化疗方案（CAP方案）应用于69例上皮性卵巢癌患者。将该疗法的结果与47例相同癌症患者采用FAM方案（包含5-氟尿嘧啶、环磷酰胺和丝裂霉素C）的结果进行回顾性比较。接受CAP方案治疗的患者5年生存率为61.6%，接受FAM方案治疗的患者为56.3%。所有9例接受CAP方案治疗的Ia期患者均无疾病，然而，13例接受FAM方案治疗的Ia期患者中有3例疾病复发并死亡。在III期和IV期有可检测病变的病例中，接受CAP方案治疗的患者有61.3%（19/31）出现反应，接受FAM方案治疗的患者有10.5%（2/19）出现反应。
